DUBLIN, Nov. 2, 2020 /PRNewswire/ — The “Global Neurodegenerative Disorder Therapeutics Market: Focus on Product, Mechanism, Route of Administration, Indication, Country Data (14 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.
The global market for neurodegenerative disorder therapeutics is predicted to grow at a CAGR of 7.21% over the forecast period of 2020-2030.
The market is driven by certain factors, which include the increasing global geriatric population, increasing incidence of chronic diseases including neurodegenerative disorder, and the presence of high unmet clinical needs regarding treatment for immune disorders, and significant external funding for executing R&D exercises.
The market is favored by the development of neurodegenerative disorder therapeutics for several clinical areas such as Multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Spinal Muscular Atrophy, Huntington disease, and other neurodegenerative disorders. The increase in the geriatric population and incurable neurodegenerative disorders across the globe are expected to translate into significantly higher demand for neurodegenerative disorder therapeutics market.
Furthermore, the companies are investing huge amounts in research and development of neurodegenerative disorder therapeutics either as a monotherapy or as combination therapy. The clinical trial landscape of different neurodegenerative disorders has been on the rise in recent years, and this will fuel the neurodegenerative disorder therapeutics market in the future.
Within the research report, the market is segmented based on indication, drug class, route of administration, and region. Each of these segments covers the market’s snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel neurodegenerative disorder therapeutics. Due to the diverse product portfolio and intense market penetration, Biogen Inc. has been a pioneer in this field and has been a significant competitor in this market.
Several other companies such as Novartis AG, F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company, among others, have launched therapies for neurodegenerative disorder, such as Mayzent (siponimod), Ocrevus (ocrelizumab), and Zeposia (ozanimod) respectively, to compete with Biogen Inc.’s Tecfidera (dimethyl fumarate) therapy market dominance.
Based on region, North America holds the largest share of neurodegenerative disorder therapeutics market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Key Topics Covered:
1 Technology Definition
2 Research Scope
3 Research Methodology
4 Market Overview
4.1 Neurodegenerative Disorder Therapeutics and Its Clinical Importance
4.2 Neurodegenerative Disorder Therapeutics Development and Commercialization Landscape
4.3 Global Neurodegenerative Disorder Therapeutics Market and Growth Potential, 2019-2030
4.4 Pricing and Reimbursement Scenario
4.5 Impact of Patent Expiry and Entry of Biosimilars on Market
4.6 Impact of COVID-19 on Neurodegenerative Disorder Therapeutics Market
5 Epidemiology of Neurodegenerative Disorder Therapeutics
6 Patent Landscape
7 Market Dynamics
7.1 Overview
7.2 Impact Analysis
7.3 Drivers
7.3.1 Rising Global Prevalence of Neurodegenerative Disorders
7.3.2 The Increase in Number of Geriatric Populations
7.3.3 Increasing Research Funding in Neurodegenerative Disorders
7.3.4 Rising Awareness about Neurodegenerative Disorders
7.4 Restraints
7.4.1 High Failure Rate of Neurodegenerative Drugs in Clinical Trials
7.4.2 Lack of Effective Drugs and Therapies
7.5 Opportunities
8 Industry Insights
8.1 Overview
8.2 Regulatory Scenario
8.3 Legal Requirements and Frameworks in the U.S.
8.3.1 Clinical Trial Authorization
8.3.2 Marketing Authorization
8.3.3 USFDA Guidelines for BLA Submission
8.3.4 Post-Authorization Regulations
8.4 Legal Requirements and Frameworks in Europe
8.4.1 EMA Biologics License Application Process
8.4.2 Centralized Procedure
8.4.3 Decentralized Procedure
8.4.4 Mutual-Recognition Procedure
8.4.5 National Procedure
8.5 Legal Requirements and Frameworks in Asia-Pacific
8.5.1 China
8.5.2 Japan
8.6 Expedited Regulatory Designations Around the World
8.7 Role of Regulatory Bodies and Consortium in Neurodegenerative Disorder Therapeutics
8.8 Regulatory Guidelines
8.8.1 Terminology Applied in Current Regulatory Guidelines for Development of Drugs to Treat Neurodegenerative Disorders
8.8.2 Actionable Recommendations
8.9 Regulatory Challenges
8.1 Reimbursement and Market Access
9 Global Neurodegenerative Disorder Therapeutics Market, by Product Type ($Million), 2019-2030
9.1 Commercialized Therapeutics
9.1.1 Multiple Sclerosis
9.1.1.1 Tecfidera
9.1.1.2 Ocrevus
9.1.1.3 Gilenya
9.1.1.4 Aubagio
9.1.1.5 Interferon (Avonex and Plegridy)
9.1.1.6 Tysabri
9.1.1.7 Rebif
9.1.1.8 Copaxone
9.1.1.9 Betaseron
9.1.1.10 Lemtrada
9.1.1.11 Mavenclad
9.1.1.12 Fampyra
9.1.1.13 Ampyra
9.1.1.14 Mayzent
9.1.1.15 Vumerity
9.1.1.16 Others
9.1.2 Epilepsy
9.1.2.1 Lyrica
9.1.2.2 Vimpat
9.1.2.3 Onfi
9.1.2.4 Keppra
9.1.2.5 Sabril
9.1.2.6 Briviact
9.1.2.7 Fycompa
9.1.2.8 Banzel
9.1.2.9 Others
9.1.3 Alzheimer’s Market
9.1.3.1 Ebixa
9.1.3.2 Namenda XR
9.1.3.3 Namzaric
9.1.3.4 Galantamine
9.1.3.5 Others
9.1.4 Parkinson’s Disease
9.1.4.1 Azilect
9.1.4.2 Neupro
9.1.4.3 Madopar
9.1.4.4 Duopa
9.1.4.5 Inbrija
9.1.4.6 Others
9.1.5 Spinal Muscular Atrophy (SMA)
9.1.5.1 Spinraza
9.1.5.2 Zolgensma
9.1.5.3 Others
9.1.6 Huntington’s Disease
9.1.6.1 Austedo
9.1.6.2 Xenazine
9.1.6.3 Others
9.2 Pipeline Therapeutics
9.2.1 Multiple Sclerosis
9.2.1.1 Zeposia
9.2.1.2 Ponesimod
9.2.1.3 Ofatumumab
9.2.1.4 Ublituximab
9.2.1.5 Ibudilast
9.2.1.6 SAR442168
9.2.2 Alzheimer’s Disease
9.2.2.1 Tricaprilin
9.2.2.2 Bryostatin-1
9.2.2.3 AGB101
9.2.2.4 COR388
9.2.2.5 TRx0237
9.2.2.6 Brexpiprazole
9.2.2.7 Semorinemab
9.2.2.8 Aducanumab
9.2.3 Parkinson’s Disease
9.2.3.1 Eltoprazine
9.2.3.2 Ongentys
9.2.3.3 IPX-066
9.2.3.4 Xadago
9.2.3.5 Nourianz
9.2.3.6 Opicapone
9.2.4 Huntington’s Disease
9.2.4.1 RG6042/IONIS -HTTrx
9.2.4.2 WVE-120101
9.2.4.3 WVE-120102
10 Global Neurodegenerative Disorder Therapeutics Market, by Drug Class ($Million), 2019-2030
10.1 Introduction
10.2 Immunomodulators
10.3 Interferons
10.4 Dopamine Agonists
10.5 Decarboxylase Inhibitors
10.6 Others
11 Global Neurodegenerative Disorder Therapeutics Market, by Indication ($Million), 2019-2030
11.1 Overview
11.2 Multiple Sclerosis
11.3 Epilepsy
11.4 Spinal Muscular Atrophy (SMA)
11.5 Alzheimer’s Disease
11.6 Parkinson’s Disease
11.7 Huntington’s Disease
11.8 Other Neurological Disorders
12 Global Neurodegenerative Disorder Therapeutics Market, by Route of Drug Administration ($Million), 2019-2030
12.1 Introduction
12.2 Oral
12.3 Injectable
12.4 Enteral
12.5 Transdermal
12.6 Others
13 Global Neurodegenerative Disorder Therapeutics Market, by Region ($Million), 2019-2030
14 Competitive Landscape
14.1 Key Developments and Strategies
14.1.1 Regulatory and Legal Developments
14.1.2 Partnerships, Alliances, and Business Expansions
14.1.3 M&A Activities
14.1.4 Funding Activities
14.2 Market Share Analysis
15 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/vaxvqz
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Regulators authorized AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population.
WASHINGTON (AP) — A former FBI lawyer was sentenced to probation for altering an email that the Justice Department relied on during its surveillance of an aide to President Donald Trump during the Russia investigation.
MADISON, Wis. (AP) — Democratic Gov. Tony Evers lashed out Friday at rival Republicans who tried to repeal his statewide mask mandate, saying killing the order would be a ridiculous move comparable to abolishing speed limits.
COLUMBIA, S.C. (AP) — As some conservatives in South Carolina celebrated getting a bill that would ban almost all abortions in the state past a legislative barrier and likely becoming law, they said they are not finished trying to end all abortions.
A Moscow court on Friday put the brother and several allies of Russian opposition leader Alexei Navalny under house arrest for two months as authorities sought to stymie more protests over the jailing of the top Kremlin foe.